ALK to Present at Two Upcoming 2013 Investor Conferences

COPENHAGEN, Denmark, Oct. 30, 2013 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Credit Suisse 2013 Healthcare Conference in Scottsdale, Arizona, USA and at the Jefferies 2013 London Healthcare Conference, UK.

Flemming Pedersen, CFO and EVP, will provide an overview of the Company and its key programmes at:

  • Credit Suisse 2013 Healthcare Conference at The Phoenix, Scottsdale, Arizona, USA on Wednesday, 13 November at 3.30 PM Mountain Standard Time

Jens Bager, President and CEO, will provide an overview of the Company and its key programmes at:

  • Jefferies 2013 London Healthcare Conference at The Waldorf Hilton, London, UK on Wednesday, 20 November at 2.20 PM Greenwich Mean Time

ALK-Abello A/S

Jens Bager
President and CEO

For further information please contact:

Investor Relations:

Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609-466-0466

Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy - a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck (MSD outside the USA and Canada) and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.

Source:ALK-Abello